openPR Logo
Press release

Multiple Sclerosis Therapeutics Market Size, Status, Top Emerging Trends, Growth and Business Opportunities 2025

07-07-2021 08:12 PM CET | Health & Medicine

Press release from: Fairfield Market Research

Multiple sclerosis has long been among the leading cause of neurological disabilities worldwide and the direct and indirect costs associated with it remain a major challenge in the multiple sclerosis therapeutics market. Nonetheless, an uptick in the patients suffering from relapsing remitting multiple sclerosis RRMS) and secondary progressive multiple sclerosis (SPMS) should spur adoption of therapeutics equipment.

Get PDF Sample Copy of this Report (Including Full TOC, List of Tables & Figures) :

https://www.fairfieldmarketresearch.com/report/multiple-sclerosis-therapeutics-market/

Lack of Trust in Generic Molecules Poses Problems in Multiple Sclerosis Therapeutics Market

The critical need for rapid-action drugs in the progressive multiple sclerosis sector is the key driver in the multiple sclerosis therapeutics market. For e.g. – Biogen Idec launched Plegridy – a long-acting variant of its interferon Avonex. Healthcare marketers must improve the safety, tolerability, and dosage of their offerings in the multiple sclerosis therapeutics market. A lack of trust due to generic molecules and biosimilars, coupled with prohibitive costs are detrimental to growth in the multiple sclerosis therapeutics market. The Blue Cross/ Blue Shield estimates that multiple sclerosis drugs in the U.S are more than twice the price of other drugs.

Hormonal Differences Make Women Significantly More Vulnerable Than Men to RRMS

The vast majority of multiple sclerosis cases are relapsing remitting multiple sclerosis. RRMS involves episodes of increasing symptoms that are followed by periods of remission. In 2013, a study conducted by the International Progressive Alliance stated that women are three times more vulnerable than men to RRMS. RRMS typically follows a clinically isolated syndrome (CIS) – with symptoms that are longer than a day. In addition, approx. half of patients progress to SPMS within a decade of being diagnosed with RRMS.

In Order to place the Purchase Query Click Here: sales@fairfieldmarketresearch.com

Convenience of Oral Therapies Explain Their Popularity in the Multiple Sclerosis Therapeutics Market

Disease modifying therapies usually target RRMS and SPMS in the multiple sclerosis therapeutics market. In terms of treatment options, consumers have expressed a clear preference for oral therapies in lieu of injectable ones. Gilenya began the oral therapy boom in 2011 and consolidated its competitive position two years later with Tecfidera – the current leader in the multiple sclerosis therapeutics market. However, oral therapies have been unable to dislodge self-injectable medication from their dominant position in the multiple sclerosis therapeutics market.

A trend of note in the multiple sclerosis therapeutics market has been the growth of infusion therapy. In 2013, Lemtrada – a drug to treat multiple sclerosis was granted regulatory approval by the European Medicines Agency (EMA). Presently, Ocrevus is the only drug approved by the FDA for treating PPMS. Newer compounds such as Zeposia and Kesimpta are likely to intensify competition in the multiple sclerosis therapeutics market. Drugs in phase three clinical trials include Fenebrutinib and Tolebrutinib.

Cash-rich Companies Leave Rivals in Dust in Multiple Sclerosis Therapeutics Market

The three most prescribed brand-name drugs in the multiple sclerosis therapeutics market are Biogen’s Tecfidera, Novartis’ Gilenya, and Roche Holding’s Ocrevus in that order respectively. Experts predict that Ocrevus has extremely promising growth prospects and should gain market share at the expense of its closest rivals. Other major brand-name drugs in the multiple sclerosis therapeutics market comprise Tysabri and Avonex (Biogen Inc.), Copaxone (Teva Pharmaceutical Industries Ltd.), Rebif (Merck KGaA), Aubagio and Lemtrada (Sanofi S.A.), and Betaferon (Bayer AG).

Browse Our Latest Reports: https://www.fairfieldmarketresearch.com/shop/

Fairfield Market Research
London, UK
UK +44 (0)20 30025888
USA +1 (844) 3829746 (Toll-free)
Email: mail@fairfieldmarketresearch.com
Follow us on LinkedIn: https://bit.ly/3voYIm9

Fairfield Market Research is a UK-based market research provider. Fairfield offers a wide spectrum of services, ranging from customized reports to consulting solutions. With a strong European footprint, Fairfield operates globally and helps businesses navigate through business cycles, with quick responses and multi-pronged approaches. The company values an eye for insightful take on global matters, ably backed by a team of exceptionally experienced researchers. With a strong repository of syndicated market research reports that are continuously published & updated to ensure the ever-changing needs of customers are met with absolute promptness.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Multiple Sclerosis Therapeutics Market Size, Status, Top Emerging Trends, Growth and Business Opportunities 2025 here

News-ID: 2323640 • Views: 375

More Releases from Fairfield Market Research

Double-digit Growth on the Anvil in Asia-Pacific Yacht Charter Market, States Fa …
The global yacht charter market is driven by an upsurge in leisure activities as consumers across demographics discover the pleasure of yachting to exotic locations. Charter yachts are immensely popular as they rival the best that luxury hotels have to offer with the added advantage of complete seclusion as any tourists can travel to a waterbody of their choice. Tourists can visit several locations in a single trip and avoid
Microbial Fuel Cell (MFC) Market Will be Worth US $15.59 Mn by 2025, Registering …
The global microbial fuel cell (MFC) market is expected to cross the growth threshold required for competitors to make lucrative gains. The total worth of the global microbial fuel cell (MFC) market is expected to supplant US $15 Mn by the end of 2025, growing at a stupendous CAGR of 9.8% during the period between 2021 and 2025. The wide spectrum of applications pertaining to microbial fuel cells is the
Global Graphite Market Poised for a Robust 8.5% CAGR for by 2025; Steelmaking, a …
One of the most desirable materials among those active in the next-generation energy sector, graphite represents a rapidly progressing, multi-billion-dollar market at a global level. Majorly fuelled by the advent of renewable energy sources, and innovations in green energy technologies, Fairfield Market Research expects the global graphite market to see a robust growth outlook during 2021 – 2025. A new report by the company forecasts a strong 8.5% CAGR for
Global Toothpaste Tablet Market to Remain Afloat as Green Practices of Personal …
Sale of toothpaste tablets is gaining momentum as a large section of the global population gravitates towards following staunch standards of personal hygiene. The global value of the toothpaste tablet market is estimated to touch US$152.3 Mn by 2026, growing at a robust CAGR of 6.8% during the period between 2021 and 2026. The past decade has witnessed a heavy uptick in advertising budgets of personal care products. This has

All 5 Releases


More Releases for RRMS

Multiple Sclerosis Drugs Market Valuable Growth Prospects and Upcoming Trends Ti …
Multiple Sclerosis Drugs Market: Introduction In terms of revenue, the multiple sclerosis drugs market is projected to expand at a CAGR of ~6% during the forecast period, due to numerous factors, about which TMR offers comprehensive insights and forecasts in the global multiple sclerosis drugs market report. Multiple sclerosis is a central nervous system disorder. It is a potentially disabling disease of the spinal cord and brain. In multiple sclerosis, the immune
The Impact Of The Coronavirus On Multiple Sclerosis Market by Top Key Players 20 …
Global Multiple Sclerosis Market research report published by market insight reports explores the current outlook in global and key regions from the perspective of Major Players, Countries, Product types and end industries. This report analyzes top players in the global market, and divides the Market into several parameters. This Multiple Sclerosis Market research report identifies the competitive landscape of industries to understand the competition at International level. This report study describes
Global Multiple Sclerosis Market Size, Global Multiple Sclerosis Market Share, G …
The Global Multiple Sclerosis Market Size is majorly driven by the factors such as rising number of consolidations between the market players for exploring the untapped market opportunity across the world. Request for Sample of This Research Report @ https://bit.ly/2Nh6b4d Top Key Player:- Hoffmann-La Roche Ltd. Bayer Healthcare AG Teva Pharmaceuticals GlaxoSmithKline AbbVie Inc. Sonafi Pasteur Pfizer Inc. Merck & Company Novartis AG AB Science Opexa Multiple Sclerosis (MS) is a disease in which the insulating covers of nerves and spinal cord are
Multiple Sclerosis Global Key Players - Biogen, Merck KGaA, Teva, Sanofi, and No …
Multiple Sclerosis Overview Multiple Sclerosis (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection, and neurodegeneration within the central nervous system. It is the most common cause of non-traumatic neurological disability in young adults, afflicting at least 2.5 million people worldwide. In most patients, the disease is characterized initially by episodes of reversible neurological deficits, which is often followed by progressive neurological deterioration over time. The precise etiology of
Secondary Progressive MS – Majority MS patients progress to SPMS indicating hu …
Multiple Sclerosis is an autoimmune disorder that happens in the Central nervous system of the body. Multiple Sclerosis involves the brain, optic nerves and the spinal cord and leads to the destruction of the insulation layer, Myelin, which covers the nerve fibers in the CNS. SPMS is characterized by a continuous increase in disability and worsening of symptoms with or without the period of relapses and remissions. As per the latest
PharmaPoint: Multiple Sclerosis - Global Drug Forecast And Market Analysis To 20 …
Multiple Sclerosis (MS) is an inflammatory autoimmune disease of the central nervous system which leads to neurological disability. The exact underlying cause of the disease is poorly understood; however, it appears to involve a complex combination of genetic susceptibility and a non-genetic trigger. The MS therapeutics market has entered an exciting phase, with an upsurge of available treatment options. Over the forecast period, patients are expected to continue to switch